← All trials
NCT02854072
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2015
- Primary completion
- May 1, 2018
- Completion date
- May 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 148
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- SamsungLead sponsor
- Yonsei UniversityStudy chair
- Chonnam National UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Daegu Catholic UniversityOverall official - principal investigator
- Hanyang UniversityOverall official - principal investigator
- Konyang UniversityOverall official - principal investigator
- Gachon UniversityOverall official - principal investigator
- The National Cancer CenterOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Korea UniversityOverall official - principal investigator
- Jeju National UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Wonju Christian HospitalOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.